European journal of nuclear medicine and molecular imaging · 2025
Fully automated volumetric assessment of tumor burden using artificial intelligence on 68Ga-PSMA-11 PET predicts survival after 177Lu-PSMA therapy in metastatic Castration-resistant prostate cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zang Shiming, Meng Qingle, Li Xiaoyuan, Guo Tiantian, Zhang Lele, Zhao Zhenyu, Yu Fei, Zhang Pengjun, Wu Wenyu, Ni Yudan, Shi Yuhang, Shao Guoqiang, Feng Youdan, Hu Lingzhi, Jia Ruipeng, Civelek A Cahid, Guo Hongqian, Wang Feng
Аннотация
PURPOSE: Despite the rapid development of artificial intelligence (AI)-powered automated segmentation tools for PET/CT imaging, their prognostic value in predicting survival outcomes remains inadequately assessed. Our objective was to explore the prognostic significance of tumor burden quantification derived from PSMA PET/CT using AI for metastatic castration-resistant prostate cancer (mCRPC) patients receiving Lutetium-177 (¹⁷⁷Lu) PSMA therapy.
METHODS: A retrospective cohort of 107 consecutive patients with mCRPC treated with ¹⁷⁷Lu-PSMA therapy were analyzed. Utilizing a deep learning algorithm, PSMA-positive lesions were automatically delineated on baseline 68Ga-PSMA-11 PET/CT scans. Key metrics were derived from the segmented lesions: total tumor volume (PSMATV), total tumor load (PSMATU = PSMATV × SUVmean), and total tumor quotient (PSMATQ = PSMATV / SUVmean). A prognostic nomogram was developed through Cox regression analysis, incorporating LASSO regularization for variable selection.
RESULTS: Univariate analysis revealed that higher PSMATV (HR 1.26), PSMATU (HR 1.18), and PSMATQ (HR 1.29) were significantly associated with shorter overall survival (OS). A prognostic nomogram that integrated PSMATQ alongside chemotherapy history, hemoglobin levels, alkaline phosphatase, and prostate-specific antigen demonstrated a bootstrap-corrected C-index of 0.71 (95% CI 0.64-0.78). Risk stratification using the nomogram showed significantly prolonged OS in low-risk vs. high-risk groups (median OS 30.9 vs. 7.9 months; HR 0.25, 95% CI 0.13-0.45, P < 0.001). The retrospective design is a study limitation.
CONCLUSION: AI-based volumetric analysis of tumor burden on PSMA PET has prognostic significance for survival in ¹⁷⁷Lu-PSMA-treated mCRPC patients. The nomogram integrating PSMATQ with clinical factors might help in personalized risk stratification, facilitating AI-aided therapeutic decision-making.
METHODS: A retrospective cohort of 107 consecutive patients with mCRPC treated with ¹⁷⁷Lu-PSMA therapy were analyzed. Utilizing a deep learning algorithm, PSMA-positive lesions were automatically delineated on baseline 68Ga-PSMA-11 PET/CT scans. Key metrics were derived from the segmented lesions: total tumor volume (PSMATV), total tumor load (PSMATU = PSMATV × SUVmean), and total tumor quotient (PSMATQ = PSMATV / SUVmean). A prognostic nomogram was developed through Cox regression analysis, incorporating LASSO regularization for variable selection.
RESULTS: Univariate analysis revealed that higher PSMATV (HR 1.26), PSMATU (HR 1.18), and PSMATQ (HR 1.29) were significantly associated with shorter overall survival (OS). A prognostic nomogram that integrated PSMATQ alongside chemotherapy history, hemoglobin levels, alkaline phosphatase, and prostate-specific antigen demonstrated a bootstrap-corrected C-index of 0.71 (95% CI 0.64-0.78). Risk stratification using the nomogram showed significantly prolonged OS in low-risk vs. high-risk groups (median OS 30.9 vs. 7.9 months; HR 0.25, 95% CI 0.13-0.45, P < 0.001). The retrospective design is a study limitation.
CONCLUSION: AI-based volumetric analysis of tumor burden on PSMA PET has prognostic significance for survival in ¹⁷⁷Lu-PSMA-treated mCRPC patients. The nomogram integrating PSMATQ with clinical factors might help in personalized risk stratification, facilitating AI-aided therapeutic decision-making.
Предметные рубрики MeSH
HumansMaleProstatic Neoplasms, Castration-ResistantGallium IsotopesAgedRetrospective StudiesLutetiumTumor BurdenGallium RadioisotopesPositron Emission Tomography Computed TomographyMiddle AgedOligopeptidesArtificial IntelligenceAutomationNeoplasm MetastasisRadioisotopesAged, 80 and overEdetic AcidPrognosisDipeptidesProstate-Specific Antigen